Current Stem Cell Research & Therapy, published by Bentham Science Publishers Ltd, is a leading journal dedicated to advancing the field of stem cell research. With an ISSN of 1574-888X and an E-ISSN of 2212-3946, this journal has been a valuable resource since its inception in 2006 and continues to broaden its scope through 2024. Recognized in the Q2 quartile for Medicine (miscellaneous) and ranked in the 66th percentile among its peers, the journal plays a crucial role in disseminating high-quality, peer-reviewed research that explores both the therapeutic and biological implications of stem cells. Located in the United Arab Emirates, Current Stem Cell Research & Therapy embraces a global audience of researchers, professionals, and students, providing a vibrant platform for discourse and innovation. While the journal offers subscription-based access, it remains committed to enhancing the scientific community's understanding of stem cell therapy and its applications across various medical fields.

APL Bioengineering is a premier open-access journal published by AIP Publishing, dedicated to advancing the field of bioengineering and its interdisciplinary applications. Established in 2017, this journal serves as a vital platform for researchers, professionals, and students interested in the critical intersections of bioengineering, biomaterials, biomedical engineering, and biophysics. With an impressive impact factor and consistent rankings in the Q1 category across multiple domains, including biochemistry and materials science, APL Bioengineering has positioned itself among the top journals in its field. The journal aims to publish innovative original research, comprehensive reviews, and insightful case studies that further the understanding and application of bioengineering principles. Since its inception, APL Bioengineering has fostered a community of thought leaders, providing open access to ensure broad dissemination of knowledge and advancements that underpin the future of biomedical innovation.

Current Opinion in Biomedical Engineering is a renowned journal published by Elsevier, focusing on the cutting-edge developments and critical assessments in the fields of biomedical engineering and related disciplines. With an ISSN of 2468-4511, it provides a valuable platform for researchers and professionals to disseminate their insights and discoveries in areas such as bioengineering, biomaterials, and medicine. Its impressive impact factor positions it in the Q2 category for several fields, including Bioengineering and Biomedical Engineering, highlighting its influence and relevance in ongoing scientific dialogues. The journal’s unique format of opinion pieces and reviews encourages innovative thinking and fosters collaboration among experts. As an essential resource for those engaged in the life sciences and engineering, Current Opinion in Biomedical Engineering serves to stimulate discussion, promote knowledge exchange, and drive advancements in biomedical applications. Set in the Netherlands at Radarweg 29, 1043 NX Amsterdam, the journal is accessible through various academic platforms, enabling a global readership to engage with the latest scholarly work in this dynamic field.

Bio-Design and Manufacturing, published by SPRINGER HEIDELBERG, is a pioneering journal that stands at the forefront of innovation in the fields of Biomedical Engineering, Biotechnology, Industrial and Manufacturing Engineering, and Materials Science. With its ISSN 2096-5524 and E-ISSN 2522-8552, this journal has established itself as a leading platform for disseminating cutting-edge research and advancements that merge biological principles with manufacturing processes, emphasizing sustainable and efficient practices. It has garnered recognition in the 2023 category quartiles, boasting a Q1 rank in all its relevant fields, which underscores its significance and impact—evident from its prime Scopus rankings that place it within the top percentiles of numerous engineering and materials science disciplines. Researchers, professionals, and students alike benefit from the wealth of knowledge presented in this journal, making it an essential resource for those seeking to enhance their understanding of bio-design applications and innovation in manufacturing processes.

Regenerative Engineering and Translational Medicine is an esteemed academic journal published by Springer Heidelberg, focusing on the interdisciplinary fields of biomaterials, biomedical engineering, and cell biology. With an ISSN of 2364-4133 and an E-ISSN of 2364-4141, the journal has carved a niche for itself since its inception in 2015, showcasing cutting-edge research that bridges the gap between scientific findings and practical applications in regenerative medicine. As a recognized platform in its field, it is currently positioned within Q3 quartiles in biomaterials, biomedical engineering, and medicine (miscellaneous), with a Scopus ranking that reflects its growing influence among peers. The journal aims to disseminate high-quality, peer-reviewed articles that highlight advancements in regenerative engineering, further advancing both theoretical and applied research. Scholars and practitioners seeking to stay at the forefront of the ever-evolving landscape of regenerative health solutions will find invaluable insights and innovations within these pages. Join a community of leading thinkers and explore the journal's comprehensive research contributions, which are crucial for fostering partnerships between academia and industry in the quest for transformative medical solutions.

Advanced Biology, published by WILEY-V C H VERLAG GMBH, serves as a premier platform where innovative research and scientific breakthroughs in the fields of biochemistry, genetics, and molecular biology converge. Established in 2021, this journal has rapidly ascended to prominence, securing Q1 rankings in its primary categories, including general biochemistry and biomedical engineering, and a solid Q2 ranking in biomaterials. With an ISSN of 2701-0198 and an emphasis on open access, Advanced Biology ensures that rigorous peer-reviewed research is accessible to a global audience, enhancing visibility and fostering collaboration among researchers, professionals, and students alike. By 2024, it aims to continually elevate scientific understanding and innovation, catering to the growing interdisciplinary nature of these critical fields. With Scopus rankings placing it amongst the top quartiles in its disciplines, Advanced Biology is poised to make significant contributions to the future of life sciences.

Acta Biomaterialia, published by Elsevier Science Ltd, is a leading journal in the fields of biochemistry, biomaterials, biomedical engineering, biotechnology, and molecular biology. With an ISSN of 1742-7061 and an E-ISSN of 1878-7568, this prestigious journal has secured a remarkable position in the academic community, evidenced by its inclusion in the Q1 category across multiple disciplines for 2023. It ranks impressively at #21 in biochemistry, #16 in biomedical engineering, #18 in biotechnology, and #11 in biomaterials, reflecting its high impact and relevance to ongoing research and development. The journal provides a platform for disseminating innovative research and advancements in the design and application of biomaterials, contributing to scientific discussions that propel the field forward. Although it does not currently offer open access options, Acta Biomaterialia continues to attract contributions that advance our understanding of biomaterials and their interactions with biological systems, ensuring that researchers, professionals, and students remain informed about the latest trends and breakthroughs in this rapidly evolving area of study.

Tissue Engineering Part C: Methods is a prestigious academic journal published by MARY ANN LIEBERT, INC, specializing in the dynamic and rapidly evolving fields of bioengineering and biomedical engineering. With an ISSN of 1937-3384 and E-ISSN 1937-3392, this journal provides a platform for the dissemination of cutting-edge research from 2008 to 2024, showcasing methodologies that advance the science of tissue engineering. Ranked in the second and third quartiles across several categories in 2023, including a notable Q2 in Biomedical Engineering, the journal is recognized for its contributions to the interface of biology and engineering. Additionally, it holds commendable Scopus ranks that highlight its influence and reach within the scientific community. Although it does not offer open access, the journal remains vital for researchers, professionals, and students seeking insightful articles that bridge the gap between theoretical research and practical application in tissues and regenerative medicine. With its rigorous peer-review process and commitment to quality, Tissue Engineering Part C: Methods continues to be an essential resource for those at the forefront of tissue engineering innovations.

CELL AND TISSUE BANKING, published by Springer, is a prominent journal dedicated to advancing the fields of biomaterials, biomedical engineering, cell biology, and transplantation. With its ISSN 1389-9333 and E-ISSN 1573-6814, the journal plays a crucial role in disseminating high-quality research from its inception in 2000 to its ongoing contributions through 2024. Situated in the Netherlands, it boasts a respectable 2023 impact factor with notable quartile rankings, positioning it within the Q3 category for biomaterials, biomedical engineering, and transplantation, and Q4 for cell biology. Furthermore, its Scopus rankings underscore its relevance and influence, particularly in the fields of medicine and engineering. Although it does not currently offer open access options, the journal remains a vital resource for researchers, professionals, and students alike, fostering innovation and knowledge transfer in the critical areas of cell and tissue sustainability.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.